MedTrace Logo

Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)

NCT01706055 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 629

Last updated 2017-03-14

No results posted yet for this study

Summary

This will be prospective, multicentre, observational study. Patients who will initiate treatment with IFNβ-1b (Betaferon) will be followed up to 6 months. Baseline visit (visit 0) i.e. treatment initiation plus four follow-up visits (visits 1-4). For each patient demographics, medical history data, safety parameters, presence of flu-like symptoms and measures to prevent or treat these symptoms will be collected.

Conditions

Interventions

BIOLOGICAL

Interferon beta-1b (Betaseron, BAY86-5046)

Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2015-09-30
Completion
2016-03-31

Countries

  • Poland

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01706055 on ClinicalTrials.gov